Larimar Therapeutics (LRMR) Treasury Shares (2013)
Larimar Therapeutics' (LRMR) quarterly Treasury Shares came in at $94.5 million in Q4 2013.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Treasury Shares (2013) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Treasury Shares for 1 consecutive years, with $94.5 million the latest figure, recorded in Q4 2013.
- For the quarter ending Q4 2013, Treasury Shares changed N/A year-over-year to $94.5 million; the trailing twelve-month figure through Dec 2013 stood at $94.5 million (changed N/A YoY), and the FY2013 full-year result was $94.5 million, up 27.7% from the prior year.
- Treasury Shares steadied at $94.5 million in Q4 2013 per LRMR's latest filing.
- Across five years, Treasury Shares topped out at $94.5 million in Q4 2013 and bottomed at $94.5 million in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 36.40 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.80 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |